NAIROBI, Kenya – The Pharmacy and Poisons Board (PPB) has issued an urgent recall for two batches of Efinox nasal drops following a labelling and packaging error that could pose significant safety risks.
In a statement released on Wednesday, the regulatory body revealed that the affected batches, Efinox 1% w/v (Batch No. 82979) and Efinox 0.5% w/v (Batch No. 82978), were found to have incorrect strength labels despite containing the correct formulations.
The error was discovered by Laboratory and Allied Limited Kenya, prompting the PPB to take immediate action.
Healthcare providers and pharmaceutical outlets across the country have been directed to cease distribution, sale, and use of the recalled batches.
The PPB also urged the public to return any products from these batches to the nearest healthcare facility or supplier to prevent potential misuse.
Efinox nasal drops are widely used to alleviate nasal congestion caused by common colds or fever, making the recall a significant concern for many households.
“The Board encourages the public to report any suspected cases of substandard medicines or adverse drug reactions to the nearest healthcare facility or directly to the Pharmacy and Poisons Board,” the statement said.
This recall underscores the PPB’s broader mandate to ensure the quality and safety of medical products under the Pharmacy and Poisons Act.
The agency has reaffirmed its commitment to protecting public health and maintaining vigilance over the pharmaceutical supply chain.
Consumers and healthcare providers are urged to remain alert and report any adverse incidents promptly as the investigation into the packaging error continues.
In a statement released on Wednesday, the regulatory body revealed that the affected batches, Efinox 1% w/v (Batch No. 82979) and Efinox 0.5% w/v (Batch No. 82978), were found to have incorrect strength labels despite containing the correct formulations.
The error was discovered by Laboratory and Allied Limited Kenya, prompting the PPB to take immediate action.
Healthcare providers and pharmaceutical outlets across the country have been directed to cease distribution, sale, and use of the recalled batches.
The PPB also urged the public to return any products from these batches to the nearest healthcare facility or supplier to prevent potential misuse.
Efinox nasal drops are widely used to alleviate nasal congestion caused by common colds or fever, making the recall a significant concern for many households.
“The Board encourages the public to report any suspected cases of substandard medicines or adverse drug reactions to the nearest healthcare facility or directly to the Pharmacy and Poisons Board,” the statement said.
This recall underscores the PPB’s broader mandate to ensure the quality and safety of medical products under the Pharmacy and Poisons Act.
The agency has reaffirmed its commitment to protecting public health and maintaining vigilance over the pharmaceutical supply chain.
Consumers and healthcare providers are urged to remain alert and report any adverse incidents promptly as the investigation into the packaging error continues.
